The activity of taxanes in the treatment of sex cord-stromal ovarian tumors

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jubilee BrownD M Gershenson

Abstract

To determine the efficacy and side effects of taxanes, with or without platinum, for the treatment of sex cord-stromal tumors of the ovary. We conducted a retrospective review of all patients seen from 1985 to 2002 at The University of Texas M.D. Anderson Cancer Center with ovarian sex cord-stromal tumors. Eligible patients underwent pathology confirmation and clinical evaluation at M.D. Anderson and received a taxane for initial or recurrent disease. Of 222 patients identified, 44 were eligible for analysis. For nine patients treated in the first-line adjuvant setting, median progression-free survival (PFS) was not reached at 51 months. Of two patients treated for measurable disease in the first-line setting, one had a complete response. Median PFS was 34.3 months; median overall survival (OS) was not reached. Median follow-up was 90.3 months (range, 39.4 to 140.5 months). Response rate for 30 patients treated with a taxane +/- platinum for recurrent, measurable disease was 42%. Median PFS was 19.6 months; median OS was not reached. Median follow-up was 100.7 months (range, 8.1 to 361.3 months). The presence of platinum correlated with response in the recurrent, measurable disease setting. The number of patients was insufficie...Continue Reading

References

Jun 4, 1987·The New England Journal of Medicine·S D WilliamsP J Loehrer
Dec 1, 1989·Obstetrics and Gynecology·P P KooningsD A Grimes
May 15, 1982·American Journal of Obstetrics and Gynecology·G L PrideM J Norgard
Mar 30, 2001·Gynecologic Oncology·J L PowellG S Henderson
Feb 21, 2004·CA: a Cancer Journal for Clinicians·Ahmedin JemalUNKNOWN American Cancer Society

❮ Previous
Next ❯

Citations

Feb 20, 2009·International Journal of Clinical Oncology·Harpreet KaurLakhbir Kaur Dhaliwal
Apr 23, 2005·Seminars in Pediatric Surgery·Daniel von Allmen
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N ColomboUNKNOWN ESMO Guidelines Working Group
May 22, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P PautierC Lhommé
Oct 25, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Isabelle Ray-CoquardNicoletta Colombo
Apr 13, 2007·Expert Opinion on Drug Metabolism & Toxicology·George P Kim, Charles Erlichman
Apr 1, 2009·Seminars in Oncology·Carolyn R Koulouris, Richard T Penson
Jul 28, 2006·Gynecologic Oncology·Stephanie A Freeman, Susan C Modesitt
Jun 17, 2005·Expert Opinion on Pharmacotherapy·Anil K SoodDavid M Gershenson
Dec 30, 2014·Gynecologic Oncology·Jane L MeiselCarol Aghajanian
May 20, 2016·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·E KempfI Duran
Jan 24, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ugo De GiorgiMarco Bregni
Apr 23, 2014·The Cochrane Database of Systematic Reviews·Mahalakshmi GurumurthySmruta Shanbhag
Dec 12, 2013·Obstetrics & Gynecology Science·Soyi LimKwang-Beom Lee
Oct 24, 2018·Pediatric Blood & Cancer·Michelle LockleyThomas A Olson
Feb 19, 2008·Expert Review of Anticancer Therapy·Maurie Markman
Dec 18, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R RanganathV Shantha
Feb 1, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ugo De GiorgiMarco Bregni
Aug 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M GershensonIsabelle Ray-Coquard
May 21, 2020·Archives of Gynecology and Obstetrics·Ying GuoYudong Wang
Nov 20, 2016·Journal of Oncology Practice·Kris Ann P SchultzA Lindsay Frazier
Sep 7, 2018·Analytical Cellular Pathology (Amsterdam)·Emina BabarovićDanijela Vrdoljak-Mozetič
Jan 14, 2021·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R Tyler Hillman, David Gershenson
Dec 21, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A F LearyUNKNOWN participants of the Fifth Ovarian Cancer Consensus Conference
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I Ray-CoquardUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Jul 11, 2021·European Journal of Obstetrics, Gynecology, and Reproductive Biology·James Nef, Daniela Emanuela Huber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.